Francisco Valdivia, MD
Neurology · Tucson, AZNPI 1568431294
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 44 manufacturers reported payments, led by Genentech USA, Inc. at 35.0% of the total. Reporting peaked in 2019 at $53,316 and has fallen 95.1% since, to $2,617 in 2025. Among neurology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 538 payments — averaging $254.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$48K
- Novartis$37K
- Amgen$18K
- AstraZeneca$15K
- EMD Serono, Inc.$8K
- AbbVie$6K
- plus $5K from 38 others
Across 20 payments — averaging $60,680 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.2M
- Genentech, Inc.$31K
- Biogen$7K
What the payments were for
- Consulting fees$24,56018%
- Speaking & faculty fees$82,03760%
- Travel & lodging$15,06111%
- Food & beverage$15,03011%
- Education$2970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCREVUS$47,388
- MAYZENT$27,149
- UPLIZNA$17,445
- Mavenclad$6,375
- UBRELVY$4,639
- SOLIRIS$2,040
- ULTOMIRIS$1,603
- KESIMPTA$857
- Ponvory$147
- ENROUTE Transcarotid Neuroprotection System$142
- ENROUTE Transcarotid Stent System$142
- ENHANCE Transcarotid Peripheral Access Kit$142
- ENROUTE 0.014 Guidewire$142
- BRIUMVI$139
- CLEVIPREX$129
- ANDEXXA$126
- ZEPOSIA$124
- Rebif$118
How this compares
$136,986 in reported general payments places this provider in the 90th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UltomirisRavulizumab-Cwvz | 17 | $1,038,856 |
| SolirisEculizumab | 13 | $663,493 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 83 | $645,822 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 17 | $386,142 |
| Kesimpta PenOfatumumab | 32 | $347,510 |
| VumerityDiroximel Fumarate | 28 | $244,498 |
| BotoxOnabotulinumtoxina | 124 | $147,487 |
| FingolimodFingolimod Hcl | 22 | $110,414 |
| AptiomEslicarbazepine Acetate | 14 | $26,322 |
| RytaryCarbidopa/Levodopa | 45 | $20,069 |
| Aimovig AutoinjectorErenumab-Aooe | 20 | $18,756 |
| NamzaricMemantine Hcl/Donepezil Hcl | 14 | $17,388 |
| Nurtec OdtRimegepant Sulfate | 12 | $14,998 |
| Memantine Hcl | 478 | $13,648 |
| Levetiracetam | 308 | $9,659 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaUltomiris, Soliris | $14,899 | $1,702,34930 claims |
| PfizerPanzyga, Nurtec Odt, Eliquis | $138 | $407,82743 claims |
| BiogenVumerity | $1,011 | $244,49828 claims |
| AbbVieBotox, Namzaric | $6,238 | $164,875138 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil | $48 | $27,760131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 388 neurology providers in Arizona.
Other neurology in Tucson
- Cynthia ReedTucson$111K
- Yeeck SimTucson$38K
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Nida LaurinScottsdale$969K
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Marwan SabbaghPhoenix$603K
- Kerry KnievelPhoenix$509K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.